Successful treatment with vincristine in PHACES syndrome.
We report a case of PHACES syndrome witch was effectively treated using vincristine. A female infant was referred at 8 months of age for evaluation with a segmental mandibular haemangioma with rapid growing and facial disfigurement. The infant was initially placed on oral prednisone with clinical response but she developed obstructive sleep apnoea. Vincristine was started at about 24 months and continued for 4 months with marked decrease in the size of the haemangioma. The only side effect was constipation.
Herrero Hernández
A
A
Division of Pediatric Oncology, Hospital Materno-Infantil Carlos Haya, Málaga, Spain. antonio.herrero.sspa@juntadeandalucia.es
Escobosa Sánchez
O
O
Acha García
T
T
D000015:Abnormalities, Multiple; D000367:Age Factors; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003248:Constipation / Q000139:chemically induced; D005124:Eye Abnormalities; D005153:Facial Neoplasms / Q000151:congenital* / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006391:Hemangioma / Q000151:congenital* / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013577:Syndrome; D013997:Time Factors; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D005938:Glucocorticoids; D014750:Vincristine; D011241:Prednisone